Phase 3 results for lilly's jaypirca® (pirtobrutinib) in covalent btk inhibitor pre-treated chronic lymphocytic leukemia or small lymphocytic lymphoma to be presented at the 2024 ash annual meeting

Results from bruin cll-321 show lilly's pirtobrutinib reduced the risk of disease progression or death by 46% compared to idelalisib plus rituximab or bendamustine plus rituximab pirtobrutinib prolonged the time to next treatment or death by a median of 23.9 months compared to 10.9 months in the control arm bruin cll-321 is the first randomized phase 3 study in cll ever conducted exclusively in patients previously treated with a btk inhibitor indianapolis , dec. 9, 2024 /prnewswire/ -- eli lilly and company (nyse: lly) today announced results from the phase 3 bruin cll-321 trial evaluating pirtobrutinib, a non-covalent (reversible) bruton's tyrosine kinase (btk) inhibitor in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (cll/sll) previously treated with a covalent btk inhibitor. the study's primary endpoint of progression-free survival (pfs) was met at primary analysis1, demonstrating pirtobrutinib was superior to investigator's choice of idelalisib plus rituximab (idelar) or bendamustine plus rituximab (br), based on independent review committee (irc) assessment.
ASH Ratings Summary
ASH Quant Ranking